leadf
logo-loader
viewSilo Pharma Inc

Silo Pharma CEO discusses latest license agreement with the University of Maryland

Silo Pharma, Inc (OTCQB:SILO) CEO Eric Weisblum talks to Proactive about the developmental stage biopharmaceutical company's latest license agreement with the University of Maryland to treat multiple sclerosis and other neuroinflammatory pathology.

Weisblum will be presenting at Proactive's One2One Investor Forum on February 23 at 1pm ET.

Quick facts: Silo Pharma Inc

Price: 0.275 USD

OTCQB:SILO
Market: OTCQB
Market Cap: $23.42 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Silo Pharma Inc named herein, including the promotion by the Company of Silo Pharma Inc in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Silo Pharma presents at Proactive's One2One virtual investor forum

Silo Pharma, Inc (OTCQB:SILO) CEO, Eric Weisblum presents at Proactive's One2One virtual investor forum. Silo Pharma is bridging the gap between traditional pharmaceuticals and the emerging psychedelics space. The developmental-stage biopharmaceutical company’s mission is to identify assets...

1 week, 3 days ago

2 min read